Seres Therapeutics, Inc. (MCRB) Free cash flow 2016–2025
Seres Therapeutics, Inc. (MCRB) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$865,000FY2025 · since FY2016: $22.4M → $865,000
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $865,000 | +100.6% |
| FY2024 | -$149.0M | -18.9% |
| FY2023 | -$125.3M | +47.5% |
| FY2022 | -$238.6M | -8191.8% |
| FY2021 | -$2.9M | +96.9% |
| FY2020 | -$94.2M | -21.5% |
| FY2019 | -$77.5M | -19.6% |
| FY2018 | -$64.8M | +19.2% |
| FY2017 | -$80.2M | -457.6% |
| FY2016 | $22.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice